A major review published in the British Medical Journal offers a polite but firm reminder that weight-loss drugs are not magic. They are more like a lease with fine print. They work impressively well, but the benefits may not stick around once the treatment ends.
Researchers analyzed dozens of studies on medications such as semaglutide and tirzepatide, which have become the headline acts in modern obesity treatment. In clinical trials, patients lost an eye-catching 15 to 20 percent of their body weight. That is the kind of result that turns skeptics into believers.
But here comes the plot twist. Once people stopped taking the drugs, the weight began creeping back, at about 0.4 kilograms per month on average. Within roughly 1.5 to 1.7 years, many were back where they started. For newer, more potent drugs, the rebound can happen even faster.
It is less a dramatic comeback and more a steady, determined return. It is like luggage that insists on arriving even after you hoped it was lost.
The health perks follow a similar script. Improvements in blood sugar, blood pressure, and heart health tend to fade as the weight returns. In short, what the drugs give, biology eventually tries to take back.
Why the reversal?
These medications work by dialing down hunger and boosting fullness. Once they are out of the system, appetite often rebounds.
Unlike traditional diet and exercise programs, which (at least in theory) build lasting habits, these drugs handle much of the heavy lifting themselves.
There is also a practical catch. About half of users stop taking the drugs within a year in real-world settings. That makes the rebound less of a surprise and more of an expectation.
The takeaway is not to dismiss these treatments—they are among the most effective tools available. But obesity is a long game. The study suggests lasting success may require longer use, better follow-up support, or pairing medication with lifestyle changes.
In plain terms, these drugs can kick-start weight loss. Keeping it off still requires a sequel plan.
